University of Tasmania
Browse

File(s) not publicly available

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials

journal contribution
posted on 2023-05-17, 09:28 authored by Andrew Palmer, Roze, S, Valentine, WJ, Smith, I, Wittrup-Jensen, KU
Background: A meta-analysis of results from four clinical trials in type 1 diabetes patients showed that insulin detemir (IDet)-based basal/bolus treatment of type 1 diabetes led to improved HbA1c (0.15%-points lower), reduced risk of major hypoglycaemic events (by 2%) and reduction in body mass index (BMI) (0.26Kg/m2) compared to protamine Hagedorn human (NPH) insulin-based basal/bolus therapy in type 1 patients. Methods: A published, validated, peer-reviewed Markov simulation model (the CORE Diabetes Model) projected short-term results obtained from the fixed-effects (weighted average) meta-analysis to long-term incidence of complications, improvements in quality-adjusted life years (QALY), long-term costs and the cost-effectiveness for IDet combinations versus NPH combinations in type 1 diabetes patients. Probabilities of complications and HbAlc-dependent adjustments were derived from the DCCT and other studies. Costs of treating complications in the UK were retrieved from published sources. Total direct costs (complications + treatment costs) for each arm were projected over patient lifetimes from a UK National Heath Service perspective. Both costs and clinical outcomes were discounted at 3.5% annually. Results: Improved glycaemic control, decreased hypoglycaemic events and BMI with IDet-based basal/bolus therapy led to fewer diabetes-related complications, an increase in quality-adjusted life expectancy of 0.09 years, increased total lifetime costs/patient of £1707 and an incremental cost-effectiveness ratio of £19,285 per QALY gained. Results were stable under a wide range of reasonable assumptions. Conclusions: Short-term improvements seen with IDet combinations versus NPH combinations led to decreased complications, improvements in QALYs and reductions in complication costs, which partially offset the additional costs of detemir, leading to a cost-effectiveness ratio which fell within a range considered to represent excellent value for money (< £35.000/QALY gained).

History

Publication title

Current Medical Research and Opinion

Volume

20

Issue

11

Pagination

1729-1746

ISSN

0300-7995

Department/School

Menzies Institute for Medical Research

Publisher

Librapharm

Place of publication

C/O Dr. Peter L Clarke, 26-32 Venture West, New Greenham Park, Newbury, England, Berkshire, Rg19 6Hx

Repository Status

  • Restricted

Socio-economic Objectives

Evaluation of health and support services not elsewhere classified

Usage metrics

    University Of Tasmania

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC